Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
TRANSLATIONAL BREAST CANCER RESEARCH（2023）
Abstract
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR + HER2 − metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
MoreTranslated text
Key words
Hormone receptor-positive human epidermal growth factor receptor,2-negative metastatic breast cancer (HR+HER2- MBC),abemaciclib,tucidinostat,personalized medicine
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined